How ECTE Could Penetrate Growing Multi-Billion Dollar Diabetes Market
Eveyone knows how much I LOVE first-to-market and proprietary products that are introduced to high growth markets!
Quite simply, the opportunity to capture market share typically increases dramatically in these instances.
Now, in order to better understand the tremendously lucrative opportunity that Echo Therapeutics, Inc. (OTCBB: ECTE) has, I’d like to describe their revolutionary, patented, one-of-a-kind Diabetes Monitoring System in more detail.
———————————————————-
Below is an image that compares ECTE’s proprietary needle-free platform technology versus the "finger stick" practice that is currently utilized to diagnose glucose levels…
As you can see, the current practice is an invasive procedure many consider painful, irritating and preventative of obtaining the most accurate readings, especially in critically ill patients that require more accurate readings.
And that gets to the core of what this unique system offers.
Now, let’s look at a more detailed snapshot of how the revolutionary ECTE System works.
Below is an image of the device that is utilized by patients and description of how it is utilized…
Top 6 Highlights of ECTE’s Patented Diabetes Monitoring System
- The ECTE System is a non-invasive, wireless, continuous blood glucose monitoring system.
- The ECTE System utilizes a novel, needle-free platform technology that increases skin permeability
- The ECTE System is an efficient, remote monitoring platform compared to platforms using needle-based technologies for accuracy
- The ECTE System has a low manufacturing cost and a razor/razor blade model with a single-use consumable
- The ECTE System has readings that are obtained every minute with a wireless data transmission to a portable monitor
- The ECTE System has a short, one-hour warm-up
————————————————————
I believe the company could be a clear target as an acquisition, especially since market acceptance could be very high.
In fact, my research indicates that it could be the only multi-billion opportunity in the Diabetic Monitoring Segment that could be (1) sold over-the-counter to patients as well as (2) sold to the 6,000 hospitals in the U.S.
Let’s face it…my research indicates it is the ONLY needle-free, continuous monitoring device that provides ACCURATE readings…at a competitive price point. And by accurate, I mean that pilot study conclusions strongly correlate with existing hospital BG measurements and are superior to handheld glucometers…all without any safety concerns being identified!
———————————————–
Keep a close watch on ECTE
!The symbol witnessed increased volume on Friday which could be a great indication of what could occur going forward.
With so many of the fundamental and technical aspects of ECTE being in the positive, this could be one of the few stocks that have more long term investment appeal for traders relative to the swing trade ideas that I more frequently present.
Best Regards,
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. ****************************************************************************************************************** The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: The LiquidTycoon employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://www.liquidtycoon.com/disclaimer Release of Liability: Through use of this website viewing or using you agree to hold LiquidTycoon, its operators owners and employees harmless and to compltely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or
otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. LiquidTycoon’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. LiquidTycoon encourages readers and investors to supplement the information in these reports with independent research and other pro advice. LiquidTycoon has agreed to be compensated one hundred fifty thousand dollars for a one month investor awareness program by a third party for ECTE. All information on featured companies is provided by the companies profiled, or is available from public sources and LiquidTycoon makes no representations, warranties or guarantees as to the accuracy or completeness of
the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. LiquidTycoon, nor any of its affiliates are not registered investment advisors or a broker dealers.
otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. LiquidTycoon’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. LiquidTycoon encourages readers and investors to supplement the information in these reports with independent research and other pro advice. LiquidTycoon has agreed to be compensated one hundred fifty thousand dollars for a one month investor awareness program by a third party for ECTE. All information on featured companies is provided by the companies profiled, or is available from public sources and LiquidTycoon makes no representations, warranties or guarantees as to the accuracy or completeness of
the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. LiquidTycoon, nor any of its affiliates are not registered investment advisors or a broker dealers.
|
|
